Characterisation of a Lunasin-Derived Anti-Inflammatory Peptide
Reynold Philip
Centre for Molecular Therapeutics, Australian Institute of Tropical Health and Medicine, James Cook University, Cairns, QLD Australia
Live Session: October 23 | 4:25 PM PDT
Back to Poster Session Schedule
Discussion Board
If you have a question about the poster, ask it here by leaving a comment for the poster presenter.
Hi Reynold,
It was great to see your presentation today. I worked on anti-inflammatory drugs and the main pathway activated by LPS is NFk-b which in turn will activate the transcription factors which controls the genes of many cytokines…so first is the NFKb pathway which you could explore to understand if your lunasin derived peptide decrease the synthesis of TNFalpha by down-regulating the NFkb: phospho IKb, p52/p65 etc.., As I said, your peptide could also downregulate the JAK/STAT pathway which is activated by cytokines, like TNFalpha…in turn, TNFalpha also activates again NFK-b pathway independently than LPS…
below some links on nfkb pathway:
https://pubmed.ncbi.nlm.nih.gov/14711835/
https://pubmed.ncbi.nlm.nih.gov/15647756/
https://pubmed.ncbi.nlm.nih.gov/8530143/
https://pubmed.ncbi.nlm.nih.gov/8530143/
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6136164/
i used many assays for testing anti-inflammatory drugs on human monocytes-derived dendritic cells (purified from PBMC)…so i can give you some information on which assay you could run in the future if you are interested in…email to: ccc4002@med.cornell.edu
Thank you Cristina Clement for attending my poster presentation. I greatly appreciate your wealth of knowledge on inflammatory drugs and pathways. I will have a look at your suggestions. Many thanks…Regards